Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$119 Mln
Revenue (TTM)
$146 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12
Industry P/E
--
EV/EBITDA
-1.9
Div. Yield
0 %
Debt to Equity
-0.8
Book Value
$--
EPS
$-10.9
Face value
--
Shares outstanding
22,543,316
CFO
$-1,163.15 Mln
EBITDA
$-1,329.38 Mln
Net Profit
$-1,439.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
| -20.9 | -38.2 | -20.9 | 55.6 | 14.4 | -11.2 | -4.2 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
| 988.3 | -21.7 | -74.6 | -47.1 | -58.5 | -19.2 | 104.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
5.8 | 119.5 | 146.1 | -196.0 | -54.0 | 81.9 | -- | 12.0 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 228.2 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers,... develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. Address: 85 Wells Avenue, Newton, MA, United States, 02459-3298 Read more
President, CEO & Director
Mr. Richard A. Paulson M.B.A.
President, CEO & Director
Mr. Richard A. Paulson M.B.A.
Headquarters
Newton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Karyopharm Therapeutics Inc (KPTI) is $5.82 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Karyopharm Therapeutics Inc (KPTI) has given a return of 14.37% in the last 3 years.
Since, TTM earnings of Karyopharm Therapeutics Inc (KPTI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.67
|
-0.45
|
|
2024
|
-0.07
|
-0.03
|
|
2023
|
-0.05
|
-0.05
|
|
2022
|
-1.85
|
-18.36
|
|
2021
|
-4.50
|
-7.01
|
The 52-week high and low of Karyopharm Therapeutics Inc (KPTI) are Rs 10.99 and Rs 3.51 as of 02-Apr-2026.
Karyopharm Therapeutics Inc (KPTI) has a market capitalisation of $ 119 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Karyopharm Therapeutics Inc (KPTI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.25
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.